January 2018

Peachey & Co LLP acted for Oncimmune Holdings plc (LSE AIM:ONC) in agreeing a framework agreement with Genostics Company Limited, part of the Gene Group (a leading healthcare company in China focused on immunological and molecular diagnostic products in the fields of oncology, pathology, haematology and cytogenetics), for an exclusive licence of its EarlyCDT technology platform in China. Under the terms of the framework agreement, Gene Group have agreed to invest £10 million for new ordinary shares in Oncimmune Holdings plc and to pay minimum royalty payments of £15.7 million on aggregate over the first 6 years following commercial launch.

back to news